Trial
NCT03917719
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Catabasis Pharmaceuticals
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
Edasalonexent
Why stopped
The Phase 3 PolarisDMD trial did not meet the primary endpoint. As a result, activities related to the development of edasalonexent have stopped including the CAT-1004-302 Open-Label Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-23